News Viatris builds in pain relief with $1.65bn Pacira purchase As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira BioSciences.
News Data backs Vertanical's cannabis therapy for back pain A phase 3 trial of Vertanical's cannabis extract in back pain has been published, and the results bode well for marketing applications under review.
News Tonix ends 16-year hiatus in fibromyalgia treatment Tonix Pharma is preparing to launch a new therapy for fibromyalgia that analysts predict could make hundreds of millions of dollars in annual sales.
News Vertex is smarting from a pain portfolio setback Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.
News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
News Lilly takes on Vertex in non-opioid pain with SiteOne buy Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.
News Third Rock in $2bn drug-hunting pact with China's Funnel New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.